2002
DOI: 10.1093/humrep/17.7.1918
|View full text |Cite
|
Sign up to set email alerts
|

Is estradiol cardioprotection a nitric oxide-mediated effect?

Abstract: The present studies do not provide evidence for an eNOS-mediated cardioprotective response to estrogen and therefore suggest that additional mechanisms other than the endothelial NO system may have an important role in the cardiovascular effects of estrogen.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0
1

Year Published

2003
2003
2015
2015

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(6 citation statements)
references
References 46 publications
0
5
0
1
Order By: Relevance
“…Among the hypothesis that may explain the protective effect of oestrogens (E) there are the following: E can suppress the synthesis of collagen and fibronectin, proteins that are increased in nephropathies [9]; E reduce the accumulation of LDL in coronary arteries, they can activate muscarinic receptors, thus stimulating endothelial cells to synthesize nitric oxide (NO) and, consequently, increase the circulating levels of nitrates and nitrites [10]. E reduce the entry of extracellular calcium into the vascular smooth muscle [11], decrease the affinity of receptors to vasoconstrictors and have a relaxing effect on vessels, decreasing levels of endothelin and norepinephrine [12], besides having antioxidant properties against ROS [13,14].…”
Section: Introductionmentioning
confidence: 99%
“…Among the hypothesis that may explain the protective effect of oestrogens (E) there are the following: E can suppress the synthesis of collagen and fibronectin, proteins that are increased in nephropathies [9]; E reduce the accumulation of LDL in coronary arteries, they can activate muscarinic receptors, thus stimulating endothelial cells to synthesize nitric oxide (NO) and, consequently, increase the circulating levels of nitrates and nitrites [10]. E reduce the entry of extracellular calcium into the vascular smooth muscle [11], decrease the affinity of receptors to vasoconstrictors and have a relaxing effect on vessels, decreasing levels of endothelin and norepinephrine [12], besides having antioxidant properties against ROS [13,14].…”
Section: Introductionmentioning
confidence: 99%
“…After treating human aortic endothelial cells with 17beta estradiol and measuring eNOS expression after 24 hour and 7 day regimens using intro-arterial infusion of interbrachial N Gmonomethyl-1-arginine, it was determined that there was no change in eNOS expression after acute or chronic estradiol treatment. A study by the same group (350) in which the vasoconstrictor response to a substrate inhibitor of nitric oxide synthase was measured in 10 healthy postmenopausal women receiving 80µg transdermal estrogen daily for four weeks also showed no difference in vasoconstrictor responses as mediated by nitric oxide.…”
Section: Estrogen and Testosteronementioning
confidence: 95%
“…Another recent study focused in on the questions as to whether estrogen's cardioprotective effect is a function of its effect on nitric oxide production (350). After treating human aortic endothelial cells with 17beta estradiol and measuring eNOS expression after 24 hour and 7 day regimens using intro-arterial infusion of interbrachial N Gmonomethyl-1-arginine, it was determined that there was no change in eNOS expression after acute or chronic estradiol treatment.…”
Section: Estrogen and Testosteronementioning
confidence: 99%
See 1 more Smart Citation
“…Por outro lado, a perda da proteção hormonal com a falência ovariana na produção de estrogênios na pós-menopausa leva ao aumento do risco de DCV 1 . Sabe-se que o papel preventivo dos esteroides sexuais femininos foi sugerido pela primeira vez há mais de meio século, o que foi confirmado por inúmeros estudos nos quais a terapia de reposição hormonal estaria associada com a redução das DCV em mulheres na pós-menopausa 2 . Contudo, mulheres com idade superior a 65 anos ou com mais de 10 anos de menopausa sofreriam o efeito contrário, ou seja, incremento do risco de DCV 3 .…”
Section: Introductionunclassified